Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

NCT03355976 is registered in ClinicalTrials.gov with Brown University as lead sponsor.

NCT NCT03355976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03355976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas
Lead sponsor
Brown University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 30, 2018
Completion date
December 31, 2026
Enrollment
46 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell adenocarcinoma, extra renal origin, fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma